Screening, diagnosis, and treatment of cancer in long-term dialysis patients

Clinical Journal of the American Society of Nephrology

Volumn 2, Issue 3, 2007, Pages 604-610

  Holley, Jean L ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC KIDNEY FAILURE; HUMAN; KIDNEY CARCINOMA; KIDNEY POLYCYSTIC DISEASE; KIDNEY TUMOR; NEOPLASM; RENAL REPLACEMENT THERAPY; REVIEW;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY DISEASES, CYSTIC; KIDNEY FAILURE, CHRONIC; KIDNEY NEOPLASMS; NEOPLASMS; RENAL DIALYSIS;

EID: 34748896515     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03931106     Document Type: Article

References (52)

1. Smith RA, Cokkinides V, Eyre HJ: American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer Clin J 56: 11-25, 2006
2. Kausz AT, Guo H, Pereira BJG, Collins AJ, Gilbertson DT: General medical care among patients with chronic kidney disease: Opportunities for improving outcomes. J Am Soc Nephrol 16: 3092-3101, 2005
3. US Renal Data System: USRDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2002
4. Buccianti G, Maisonneuve P, Ravasi B, Cresseri D, Locatelli F, Boyle P: Cancer among patients on renal replacement therapy: A population-based survey in Lombardy, Italy. Int J Cancer 66: 591-593, 1996
5. Maisonneuve P, Agoda L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney APS, Briggs D, McCredie M, Boyle P: Cancer in patients on dialysis for end-stage renal disease: An international collaborative study. Lancet 354: 93-99, 1999
6. Heidland A, Bahner U, Vamvakas S: Incidence and spectrum of dialysis-associated cancer in three continents. Am J Kidney Dis 35: 347-353, 2000
7. Chen K-S, Lai M-K, Huang C-C, Chu S-H, Leu M-L: Urologic cancers in uremic patients. Am J Kidney Dis 25: 694-700, 1995
8. Port FK, Ragheb NE, Schwartz AG, Hawthorne VM: Neoplasms in dialysis patients: A population-based study. Am J Kidney Dis 14: 119-223, 1989
9. Farivar-Mohseni H, Perlmutter AE, Wilson S, Shingleton WB, Bigler SA, Fowler JE: Renal cell carcinoma and end stage renal disease. J Urol 175: 2018-2021, 2006
10. Slifkin RF, Goldberg J, Neff MS, Baez A, Matto N, Gupta S: Malignancy in end-stage renal disease. Trans Am Soc Artif Intern Organs 13: 34-39, 1977
11. Shell AG, Flavel S, Disney AP: Cancer development in patients progressing to dialysis and renal transplantation. Transplant Proc 17: 1685-1688, 1985
12. Gulanikar AC, Daily PP, Kilambi NK, Hamrick-Turner JE, Butkus KE: Prospective pretransplant ultrasound screening in 206 patients for acquired renal cysts and renal cell carcinoma. Transplantation 66: 1669-1672, 1998
13. LeBrun CL, Diehl LF, Abbott KD, Welch PG, Yuan CM: Life expectancy benefits of cancer screening in the end-stage renal disease population. Am J Kidney Dis 35: 237-243, 2000
14. Kajbaf S, Nichol G, Zimmerman D: Cancer screening and life expectancy of Canadian patients with kidney failure. Nephrol Dial Transplant 17: 1786-1789, 2002
15. Chertow GM, Paltiel AD, Owen WF, Lazarus JM: Cost-effectiveness of cancer screening in end-stage renal disease. Arch Intern Med 156: 1345-1350, 1996
16. LeBrun CJ, Yuan CM, Welch PG: A reconsideration of the benefits of cancer screening in dialysis patients. Semin Dial 12: 140-143, 1999
17. Holley JL: Preventive medical screening is not appropriate for many chronic dialysis patients. Semin Dial 13: 369-371, 2000
18. Evans AJ, Cohen EJ, Cohen GF: Patterns of breast calcification in patients on renal dialysis. Clin Radiol 45: 343-344, 1992
19. Castellanos M, Varma S, Ahem K, Grosso S-A, Buchbinder S, D'Angelo D, Raia C, Kleiner M, Elsayegh S: Increased breast calcifications in women with ESRD on dialysis: Implications for breast cancer screening. Am J Kidney Dis 48: 301-306, 2006
20. Akmal M, Swaelson S, Karubian F, Gadallah M: The prevalence and significance of occult blood loss in patients with predialysis advanced chronic renal failure receiving dialytic therapy. Clin Nephrol 42: 198-202, 1994
21. Bini EJ, Kinkhabwala A, Goldfarb DS: Predictive value of a positive fecal occult blood test increases as the severity of CKD worsens. Am J Kidney Dis 48: 580-586, 2006
22. Morton JJ, Howe SF, Lowell JA, Stratta RJ, Taylor RJ: Influence of end-stage renal disease and renal transplantation on serum prostate-specific antigen. Br J Urol 75: 498-501, 1995
23. Bruun L, Bjork T, Lilja H, Becker C, Gustafsson O, Christensson A: Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment. Nephrol Dial Transplant 18: 598-602, 2003
24. Djavan B, Shariat S, Ghawidel K, Guven-Marberger K, Remzi M, Kovarik J, Hoerl WH, Marberger M: Impact of chronic dialysis on serum PSA, free PSA, and free/total PSA ratio: Is prostate cancer detection compromised in patients receiving long-term dialysis? Urology 53: 1169-1174, 1999
25. International Early Lung Cancer Action Program Investigators; Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS: Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 355: 1763-1771, 2006
26. Henschke CI, Yankelevitz DF, Miettinen OS; I-ELCAP Investigators: Computed tomographic screening for lung cancer: The relationship of disease stage to tumor size. Arch Intern Med 166: 321-325, 2006
27. Ishikawa I: Acquired cystic disease: Mechanisms and manifestations. Semin Nephrol 11: 671-684, 1991
28. Ishikawa I, Saito Y, Shikura N, Kitada H, Shinoda A, Suzuki S: Ten year prospective study on the development of renal cell carcinoma in dialysis patients. Am J Kidney Dis 16: 452-458, 1990
29. Grantham JJ: Acquired cystic kidney disease. Kidney Int 40: 143-152, 1991
30. Fick GM, Gabow PA: Hereditary and acquired cystic disease of the kidney. Kidney Int 46: 951-964, 1994
31. Sarasin FP, Wong JB, Levey AS, Meyer KB: Screening for acquired cystic kidney disease: A decision analytic perspective, Kidney Int 48: 207-219, 1995
32. Lye WC, Tambyah P, Leong SO, Lee EJC: Serum tumor markers in patients on dialysis and kidney transplantation. Adv Perit Dial 10: 109-111, 1994
33. Fiella X, Cases A, Molina R, Jo J, Bedini JL, Revert L, Ballesta AM: Tumor markers in patients with chronic renal failure. Int J Biol Markers 5: 85-88, 1990
34. Odagiri E, Jibiki K, Takeda M, Sugimura H, Iwachika C, Abe Y, Kihara K, Kihara Y, Itou M, Nomura T, et al.: Effect of hemodialysis on the concentration of the seven tumor markers carcinoembryonic antigen, alpha-fetoprotein, squamous cell carcinoma-related antigen, neuron-specific enolase, CA 125, CA 19-9, and CA15-3 in uremic patients. Am J Nephrol 11: 363-368, 1991
35. Zeimet AG, Marth C, Offner FA, Obrist P, Uhi-Steidl M, Feichtinger H, Stadlmann S, Daxenbichler G, Dapunt O: Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol Oncol 62: 384-389, 1996
36. Fussholler A, Grabensee B, Plum J: Effluent CA 125 concentration in chronic peritoneal dialysis patients: Influence of PD duration, peritoneal transport, and PD regimen. Kidney Blood Press Res 26: 118-122, 2003
37. Sevinc A, Buyukberber S, Sari R, Kiroglu Y, Turk HM, Ates M: Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids. Gynecol Oncol 77: 254-257, 2000
38. Townsend RR, Cohen DL, Katholi R, Swan SK, Davies BE, Bensel K, Lambrecht L, Parker J: Safety of gadolinium (GO-BOPTA) infusion in patients with renal insufficiency. Am J Kidney Dis 36: 1207-1212, 2000
39. Tombach B, Bremer C, Reimer P, Matzkies F, Schaefer RM, Evert W, Geens V, Eisele J, Heindel W: Using highly concentrated gadobutrol as an MR contrast agent in patients also requiring hemodialysis: Safety and dialysability. AJR Am J Roentgenol 178: 105-109, 2002
40. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS: Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17: 2359-2362, 2006
41. Boyd AS, Zic JA, Abraham JL: Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56: 27-30, 2007
42. Sam AD, Morasch MD, Collins J, Song G, Chen R, Pereles FS: Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg 38: 313-318, 2003
43. Crosbie EJ, Kitchener HC: Human papillomavirus in cervical screening and vaccination. Clin Sci 110: 543-552, 2006
44. Ault KA: Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: A review. Obstet Gynecol Surv 61[Suppl 1]: S26-S31, 2006
45. ACOG Office of Communications: ACOG News Release: ACOG releases HPV vaccine recommendations for Ob-Gyns Aug 8, 2006. Available at: http:// www.acog.org/from_home/publications/press_releases/nr08-08-06.cfm. Accessed November 2006
46. Kuehn BM: CDC panel backs routine HPV vaccination. JAMA 296: 640-641, 2006
47. Eneman JD: Cancer management in patients with end-stage renal disease. Oncology 19: 1199-1212, discussion 1212-1214, 2005
48. Hoist JP, Burman KD, Atkins F, Umans JG, Jonklaas J: Radioiodine therapy for thyroid cancer and hyperthyroidism in patients with end-stage renal disease on hemodialysis. Thyroid 15: 1321-1331, 2005
49. Patel P, Henry LL, Ganti AK, Potti A: Clinical course of lung cancer in patients with chronic kidney disease. Lung Cancer 43: 297-300, 2004
50. Tsuchida M, Yamato Y, Aoki T, Watanabe T, Hashimoto T, Shinohara H, Hayashi J: Complications associated with pulmonary resection in lung cancer patients on dialysis. Ann Thorac Surg 71: 435-438, 2001
51. Ciriaco P, Casiraghi M, Melloni G, Carretta A, Libretti L, Augello G, Zannini P: Pulmonary resection for non-small-cell lung cancer in patient son hemodialysis: Clinical outcome and long-term results. World J Surg 29: 1516-1519, 2005
52. Wu C-F, Shee J-J, Ho D-R, Chen W-C, Chen C-S: Different treatment strategies for end stage renal disease in patients with transitional cell carcinoma. J Urol 171: 126-129, 2004